DXCM Dexcom Inc

Price (delayed)

$358.74

Market cap

$34.69B

P/E Ratio

66.31

Dividend/share

N/A

EPS

$5.41

Enterprise value

$35.78B

Sector: Healthcare
Industry: Diagnostics & Research

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in ...

Highlights

The company's equity has surged by 104% YoY and by 4.2% QoQ
The stock's price to earnings (P/E) is 45% less than its last 4 quarters average of 121.3
The debt has soared by 56% YoY
The quick ratio has declined by 3.6% year-on-year

Key stats

What are the main financial stats of DXCM
Market
Shares outstanding
96.71M
Market cap
$34.69B
Enterprise value
$35.78B
Valuations
Price to earnings (P/E)
66.31
Price to book (P/B)
18.13
Price to sales (P/S)
17.05
EV/EBIT
112.54
EV/EBITDA
91.06
EV/Sales
17.65
Earnings
Revenue
$2.03B
EBIT
$317.9M
EBITDA
$392.9M
Free cash flow
$236M
Per share
EPS
$5.41
Free cash flow per share
$2.45
Book value per share
$19.79
Revenue per share
$21.04
TBVPS
$45.39
Balance sheet
Total assets
$4.39B
Total liabilities
$2.49B
Debt
$1.82B
Equity
$1.9B
Working capital
$2.84B
Liquidity
Debt to equity
0.96
Current ratio
5.7
Quick ratio
5.09
Net debt/EBITDA
2.76
Margins
EBITDA margin
19.4%
Gross margin
67.5%
Net margin
25.4%
Operating margin
15.4%
Efficiency
Return on assets
12.8%
Return on equity
31.2%
Return on invested capital
7%
Return on capital employed
8.4%
Return on sales
15.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DXCM stock price

How has the Dexcom stock price performed over time
Intraday
0.39%
1 week
-7.09%
1 month
-2.89%
1 year
-11.28%
YTD
-2.97%
QTD
-0.18%

Financial performance

How have Dexcom's revenue and profit performed over time
Revenue
$2.03B
Gross profit
$1.37B
Operating income
$311.8M
Net income
$514M
Gross margin
67.5%
Net margin
25.4%
The net margin has soared by 176% YoY
DXCM's operating income has surged by 64% year-on-year and by 4.1% since the previous quarter
DXCM's gross profit is up by 34% year-on-year and by 7% since the previous quarter
The operating margin has increased by 29% year-on-year

Growth

What is Dexcom's growth rate over time

Valuation

What is Dexcom stock price valuation
P/E
66.31
P/B
18.13
P/S
17.05
EV/EBIT
112.54
EV/EBITDA
91.06
EV/Sales
17.65
The stock's price to earnings (P/E) is 45% less than its last 4 quarters average of 121.3
The EPS rose by 3.4% QoQ
The company's equity has surged by 104% YoY and by 4.2% QoQ
DXCM's P/B is 21% below its last 4 quarters average of 22.9 and 10% below its 5-year quarterly average of 20.2
The stock's price to sales (P/S) is 35% more than its 5-year quarterly average of 12.6 but 14% less than its last 4 quarters average of 19.8
Dexcom's revenue has increased by 27% YoY and by 5% from the previous quarter

Efficiency

How efficient is Dexcom business performance
Dexcom's ROA has soared by 97% YoY but it has decreased by 9% from the previous quarter
The ROE has soared by 72% year-on-year but it is down by 11% since the previous quarter
DXCM's return on invested capital is down by 18% year-on-year and by 9% since the previous quarter
The ROS rose by 17% YoY but it fell by 2.5% QoQ

Dividends

What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DXCM.

Financial health

How did Dexcom financials performed over time
The company's total assets is 77% higher than its total liabilities
The company's total assets has surged by 79% YoY and by 2.3% QoQ
The total liabilities has surged by 64% year-on-year
The debt is 4.5% less than the equity
The company's equity has surged by 104% YoY and by 4.2% QoQ
The debt has soared by 56% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.